Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The company will review FDA's response and decide on appropriate next steps soon.
Subscribe To Our Newsletter & Stay Updated